Related Experiment Video

Updated: Aug 5, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

RAS Inhibitors: Changing the Paradigm from the Undruggable

Federica Campana1, Emanuela De Bellis2, Floriana Porcaro3

  • 1Department of Human, Philosophical and Formation Sciences, University of Salerno, 84084 Fisciano, Italy.

Pharmaceutics
|July 28, 2026
PubMed

Insights

RAS mutations were historically challenging drug targets. Recent KRAS G12C inhibitors like sotorasib and adagrasib have advanced RAS inhibitor development, offering new treatment options.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • RAS mutations are common in cancer but historically undruggable.
  • Previous attempts to inhibit RAS proteins pharmacologically were unsuccessful.
  • The emergence of targeted therapies has shifted the paradigm.

Purpose of the Study:

  • To provide an updated summary of RAS inhibitor drugs.
  • To detail the mechanism of action, pharmacokinetics, and toxicity of these inhibitors.
  • To review efficacy studies of novel RAS-targeted therapies.

Main Methods:

  • Literature review of recent advancements in RAS inhibitor development.
  • Analysis of published data on drug efficacy, pharmacokinetics, and safety.
  • Synthesis of information on various RAS inhibitor classes and their targets.

Main Results:

  • KRAS G12C inhibitors (sotorasib, adagrasib) represent a breakthrough.
  • The RAS inhibitor landscape now includes diverse compounds with varied mechanisms.
  • New drugs demonstrate promising efficacy in clinical studies.

Conclusions:

  • Targeting RAS mutations is now a viable therapeutic strategy.
  • Continued research is essential for optimizing RAS-targeted therapies.
  • These inhibitors offer new hope for patients with RAS-mutated cancers.
Keywords:
RAS mutationsRAS-inhibitorssolid tumors

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...